Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Cipla Not Ready For U.S. Biosimilars Market Even As Peers Line Up For Bigger Piece Of Pie

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Cipla - India's largest drug maker by market share - will not be amongst the first bunch of companies that prepare to launch biosimilars in the U.S
Advertisement

Related Content

On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era
On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era
Indian Court Says "No" To Linking Patents With Regulatory Approvals; Sends Back Six Patent Oppositions
India's Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10
Playing Catch-Up: Mylan And Biocon To Team Up On Generic Biologics
Advertisement
UsernamePublicRestriction

Register

SC074430

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel